placed at the right atrial appendage (RAA).
With a programmable electric stimulator (Cardiac Stimulator BC-03, Fukuda Densi, Tokyo, Japan) with rectangular current pulses of 2-ms duration at twice the diastolic threshold, we delivered programmed, single, premature atrial stimuli (S2) after a train of 8 atrial paced beats (S1) at a cycle length of 500 ms from the RAA.
During this study, signals from ECG leads I, aVF, V1, and V5 were recorded simultaneously with the stimulus artifact from the pacing site and with bipolar electrograms from the other electrode sites. The electrograms were filtered at a bandpass of 0.1-500 Hz, and the endocardial electrograms between 30 and 400 Hz were recorded with a computing electric recorder (EPL00372-001-07, EP Lab, Quinton, Canada). The coupling interval between S1 and S2 was reduced in 10-ms steps until S2 was no longer captured.
Definitions
In the present study, S1 and A1 refer to the driving stimulus and the atrial deflection of the basic rhythm, respectively. S2 and A2 refer to the extrastimulus and the deflection resulting from it, respectively, as previously reported. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] The effective refractory period of the right atrium (ERP-A) was defined as the longest S1-S2 interval that did not elicit an atrial depolarization. The conduction time from the stimulus artifact to the distal electrode pair placed at the coronary sinus was measured as the intra-atrial conduction time during the single premature stimulation to the RAA.
RAF was defined as the occurrence of 2 or more successive atrial complexes with a return cycle (A2 -A3) ≤250 ms and a subsequent cycle length (CL) ≤300 ms (14) . Fragmented atrial activity (FAA) was defined as the occurrence of disorganized atrial activity ≥150% of the duration of the local atrial activity in basic beats recorded on the right atrial electrogram. 19 The intra-atrial conduction time (CT) at baseline was defined as the conduction time from the stimulus artifact to the distal electrode pair placed at the coronary sinus during the stimulation at a CL of 500 ms delivered to the RAA (S1A1). Intra-atrial conduction delay (CD) was defined as the presence of an increase in S2A2 ≥20 ms as compared with the S1A1 for the basic drive, which was measured from the distal electrode pair placed at the coronary sinus (3 cm from the ostium of the coronary sinus). 20 The zones of RAF (RAFZ), fragmented atrial activity (FAAZ), and conduction delay (CDZ) were defined as the range between the longest and the shortest S1-S2 intervals that elicit RAF, FAA, and CD, respectively. When RAF, FAA, or CD was induced at only 1 coupling interval, the zone was expressed as 10 ms. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] Each electrophysiologic index was measured before and 5 min after completion of infusion of flecainide at a dose of 2 mg/kg over 10 min. Flecainide was administered via the subclavian vein. Atrial fibrillation was defined as the occurrence of irregular atrial rhythm lasting more than 30 min. We investigated the relationship between the ERP-A in the baseline study and the change in the ERP-A after flecainide administration, and also investigated the relationship between the change in the ERP-A and the change in the maximum CD (Max.CD) after flecainide administration.
The patients were divided into 2 groups: those in whom RAF was induced and those in whom RAF was not induced in the baseline study before flecainide was administered. The electrophysiologic properties of the atrial tissue were compared between the 2 groups.
Plasma Drug Concentration Studies
Blood samples were taken immediately before and immediately after the electrophysiologic studies following flecainide administration, and the plasma concentration of flecainide was determined in each sample by a specific and accurate high performance liquid churomatograhy technique as previously described. 21 
Statistical Analysis
Values are expressed as mean ± standard deviation. Differences were analyzed for significance by the paired t-test or unpaired t-test. Linear regression was used to analyze the relationship among the ERP-A in the baseline study, the change in the ERP-A and the change in the Max.CD upon flecainide administration. A value of p<0.05 was considered to be significant.
Results

Electrophysiological Changes After Intravenous Flecainide
Flecainide significantly prolonged the ERP-A (213±31 to 240±35 ms, p<0.0001) and conduction time (124±22 to 154±28 ms, p<0.0001), but did not significantly change the Max.CD (64±24 to 62±29 ms, p=0.67). Flecainide significantly reduced the RAFZ (22±27 to 11±22 ms, p<0.05), but did not significantly affect the FAAZ (35±27 to 32±30 ms, p=0.64) or CDZ (56±25 to 48±27 ms, p=0.15) ( Table 1) . Flecainide significantly increased the atrial threshold (0.8± 0.2 to 1.0±0.3, p<0.0001). The sequence of atrial electric potential was unchanged before and after flecainide administration.
Effects of Flecainide on RAF
During the baseline study, RAF was induced in 18 [47%; age (mean ± standard deviation) 55±9 years] of the 38 patients: 9 of the 19 patients with WPW syndrome, 4 of the 11 patients with AVNRT, 1 of the 3 patients with atrial flutter, 2 of the 3 patients with SSS, the 1 patient with VT, and the 1 patient with PAF. RAF was induced in 6 (60%) of the 10 patients with AF and in 12 (43%) of the 28 patients without AF. Although there was a significant difference in age, there were no significant differences in the left ventricular ejection fraction or the left atrial dimension between the patients in whom RAF was or was not induced in the baseline study (Table 2) .
After flecainide administration, RAF was abolished in 11 (61%) of the 18 patients with it (Fig 1) , whereas RAF was newly induced in 5 (25%) of the 20 patients who had not exhibited RAF in the baseline study. The electrophysiological parameters were not measured in 2 of these 20 patients because sustained AF was induced by flecainide (Fig 2) .
Atrial Refractoriness and Conduction Before and After Flecainide in the Patients Who Did or Did Not Have RAF at Baseline
The ERP-A was significantly shorter among the patients with RAF than among those who did not have RAF in the baseline study (202±22 vs 224±34 ms, p<0.05). The Max.CD was significantly longer among the patients with RAF than among those who did not have RAF (77±17 vs 51±23 ms, p<0.001). However, there was no significant difference in the CT of the basic CL between the patients who did or did not have RAF in the baseline study (127±26 vs 121±18 ms). Flecainide significantly prolonged the ERP-A in the patients with RAF (202±22 to 238±33 ms, p<0.001), whereas it had no significant effect on the ERP-A in the patients without RAF (224±34 to 242±38 ms). Flecainide significantly prolonged the CT in both the patients with RAF (127±26 to 164±29 ms, p<0.0001) and those without RAF (121±18 to 145±25 ms, p<0.0001). Flecainide significantly reduced the Max.CD in the patients with RAF (77±17 to 63±32 ms, p<0.05), but did not significantly affect Max.CD in the patients without RAF (51±23 to 60±26) (Fig 3) . Flecainide significantly increased the atrial threshold in the patients with RAF (0.9±0.1 to 1.0±0.3, p<0.05) and without RAF (0.8±0.2 to 1.0±0.2, p<0.001).
RAFZ, FAAZ, and CDZ Before and After Flecainide in the Patients Who Did or Did Not Have RAF at Baseline
The RAFZ (43±22 vs 0±0 ms, p<0.0001), FAAZ (51±22 vs 18±22 ms, p<0.001), and CDZ (70±21 vs 42±22 ms, p< 0.001) were significantly longer in the patients with RAF than in those without RAF in the baseline study.
Flecainide significantly reduced the RAFZ in the patients with RAF (43±22 to 13±19 ms, p<0.0001), but had no significant effect on the RAFZ in those without RAF (0±0 to 9±24 ms). Flecainide significantly reduced the FAAZ in the patients with RAF (51±22 to 28±26 ms, p<0.001), whereas it significantly increased the FAAZ in those without RAF (18±22 to 37±34 ms, p<0.05). Flecainide significantly reduced the CDZ in the patients with RAF (70±21 to 48±30 ms, p<0.01), but had no significant effect on the CDZ in those without RAF (42±22 to 49±24 ms) (Fig 4) .
ERP-A at Baseline and the Changes in the ERP-A and Max.CD After Flecainide Administration
There was a significant negative correlation between the ERP-A in the baseline study and the change in ERP-A after flecainide administration (n=36, r=0.45, p<0.01; Fig 5) . There was a significant negative correlation between the administration (n=36, r=0.70, p<0.0001; Fig 6) .
Plasma Drug Concentration Study
The plasma flecainide concentration was 617±294 (mean ± standard deviation) ng/ml immediately before the electrophysiologic studies were performed, and 338± 129 ng/ml immediately after, which suggests that the plasma concentration of flecainide in our electrophysiologic study was within the therapeutic range. 22 There were no significant differences in the plasma flecainide concentration between the patients with RAF and those without RAF before the electrophysiologic studies (645±310 vs 583± 285 ng/ml), nor immediately after the electrophysiologic studies (331±116 vs 307±70 ng/ml).
Discussion
There are several limitations to clinical electrophysiological studies of PAF. Investigations based on recordings of local abnormal atrial electrograms occurring during sinus rhythm and abnormal responses elicited by premature atrial stimulation, including RAF, FAA, and intra-atrial CD, have provided information on the electrophysiological properties of the diseased atrium, [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] and although these responses do not directly demonstrate the existence of AF, they are closely related to its development and maintenance in predisposed patients. 11 Some investigators have reported that RAF is a nonspecific response of atrial muscle, and therefore is not a reliable parameter of a tendency to spontaneously develop AF, 14, 16 but the RAFZ has shown a significant difference between patients with idiopathic PAF and control subjects. 20 The RAF could therefore be used as an index of tendency toward atrial arrhythmia.
Effect of Flecainide on Atrial Refractoriness and Conduction
There are reports concerning the effects of flecainide on atrial refractoriness and conduction in humans. Pop and Treese reported that flecainide prolonged the ERP-A in patients with increased atrial vulnerability 5 and Matsuo et al reported that flecainide prolonged the ERP-A and reduced the Max.CD in patients with PAF. 4 However, those reports are of the effects of flecainide on abnormal atrial tissue and to our knowledge, there has not been a report on the relationship between the changes in atrial electrophysiologic properties induced by flecainide and the induction of an abnormal atrial response such as RAF.
In the present study, flecainide significantly prolonged the ERP-A and CT, in agreement with previous studies, 4,5 but did not change the Max.CD. Flecainide significantly prolonged the ERP-A in the patients who had RAF in the baseline study, but had no significant effect on the ERP-A in those without RAF. Flecainide reduced the Max.CD in the patients with RAF, but had no effect on the Max.CD in those without RAF. Fig 5 shows the negative correlation between the ERP-A in the baseline study and the degree of prolongation of ERP-A after flecainide administration, and Fig 6 shows the negative correlation between the change in the ERP-A and the change in the Max.CD after flecainide administration. These present findings suggest that the prolongation of the ERP-A by flecainide is one of explanations why Max.CD reduced after flecainide administration. Thus, the degree of change in the ERP-A and Max.CD after flecainide administration may be dependent on the electrophysiological characteristics in the baseline study.
RAF was suppressed after flecainide administration in the patients (as shown in Fig 1) , even though the degree of prolongation of ERP-A did not exceed the maximum coupling interval of the extrastimulus that induced RAF in the baseline study. On the other hand, RAF was newly induced by the same coupling interval of extrastimulus and it changed to sustained AF after flecainide administration in 2 patients (Fig 2) . These findings suggest that induction of RAF may depend on not only the ERP-A, but also the Max CD, as previously described. 17 
Effects of Flecainide on Atrial Vulnerability
In the present study, we measured several parameters reflecting the electrophysiologic properties of the atrial muscle, including the RAFZ, FAAZ, and CDZ, before and after infusion of flecainide. These zones were reduced by flecainide in the patients with RAF, but were increased in those without RAF. Although further studies are necessary to determine whether these properties can be used to assess antiarrhythmic efficacy and/or pro-arrhythmic potentiality, our findings indicate that flecainide has the potential to prevent the initiation of PAF in patients with RAF and to induce it in those without RAF.
Of the 18 patients with RAF in the baseline study, 11 (61%) did not develop RAF after flecainide administration. On the other hand, flecainide newly induced RAF in 5 patients (5 of 20) and AF in 2 patients (2 of 20) of those without RAF in the baseline study. These findings indicate that flecainide reduces atrial vulnerability in patients with RAF and increases it in patients without RAF.
The RAFZ were shortened in almost all the patients with RAF. The ERP-A was decreased and Max.CD was increased larger in the patients with newly induced RAF (Fig 6) . However, there was no specific electrophysiologic properties before administration of flecainide to predict newly induced RAF or sustained AF.
It is thought that the mechanism of RAF is local re-entry, and that of FAA is local continuous activity in response to premature beats. 23 The change of ERP-A in the present patients with RAF was larger than that in patients without RAF. Therefore, there was a reduction in the RAFZ, FAAZ and CDZ in patients with RAF with a larger change of ERP-A, whereas the zones of these markers were increased and RAF was newly induced in some patients mainly because of the increased CD in patients without RAF.
Effects of Flecainide and Other Antiarrhythmic Agents on Electrophysiological Properties of Atrial Vulnerability
In the present study, flecainide significantly prolonged the ERP-A and significantly reduced the Max.CD, RAFZ, FAAZ and CDZ in patients with RAF. On the other hand, it significantly increased the conduction time and FAAZ, but did not change the ERP-A, Max.CD, RAF or CDZ in the patients who did not have RAF. These results are similar to the changes in atrial electrophysiologic properties after cibenzoline administration. 8 Disopyramide prolonged the refractory period and wavelength index in patients with RAF and those without RAF, but the percentage changes in the refractory period and wavelength were larger in the patients with RAF than in those without RAF. 12, 24 These findings indicate that class I antiarrhythmic drugs may preferentially act on the substrate of RAF or AF.
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Study Limitations
First, there was not a placebo group. Because all patients received flecainide, the true rates of drug-related suppression of RAF and induction of AF are unclear. Second, RAF or AF in diseased human atria cannot always be explained by reentry and may sometimes be caused by triggered activity. 25 Third, it is known that the atria have significant electrophysiological heterogeneity, [26] [27] [28] and that flecainide has anisotropic effects on the wavelength. 29 By measuring at a single position, it is very difficult to conclusively demonstrate the effects of flecainide on the trigger and substrate of AF. Fourth, the plasma flecainide concentration decreased immediately after the electrophysiologic studies, although it was within the therapeutic range during the electrophysiologic study. Fifth, the atrial electophysiologcal properties are affected by sympathetic nerve activity and flecainide augments muscle sympathetic nerve activity. 30 We did not investigate the preventive effect of flecainide. However, the widening of the RAFZ, FAAZ and CDZ is closely related to spontaneously occurring episodes of AF. 11 Therefore the narrowing of these zones may be related to the prevention of AF.
Conclusion
In summary, our study demonstrated that flecainide induced significant prolongation of the ERP-A among the electrophysiological properties of the patients with RAF who had a relatively short ERP-A and long Max.CD in the baseline study. Thus, flecainide may preferentially affect the substrate for RAF or AF, mainly by inducing prolongation of atrial refractoriness and/or by resulting in reduction of the Max.CD. On the other hand, flecainide may worsen the atrial vulnerability of the electrophysiological properties of patients without RAF, mainly by prolonging the conduction delay.
